JP2018521011A5 - - Google Patents

Download PDF

Info

Publication number
JP2018521011A5
JP2018521011A5 JP2017561677A JP2017561677A JP2018521011A5 JP 2018521011 A5 JP2018521011 A5 JP 2018521011A5 JP 2017561677 A JP2017561677 A JP 2017561677A JP 2017561677 A JP2017561677 A JP 2017561677A JP 2018521011 A5 JP2018521011 A5 JP 2018521011A5
Authority
JP
Japan
Prior art keywords
cancer
composition
composition according
polynucleotide
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017561677A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018521011A (ja
JP6792294B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/033817 external-priority patent/WO2016196062A1/en
Publication of JP2018521011A publication Critical patent/JP2018521011A/ja
Publication of JP2018521011A5 publication Critical patent/JP2018521011A5/ja
Application granted granted Critical
Publication of JP6792294B2 publication Critical patent/JP6792294B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017561677A 2015-05-29 2016-05-23 肺のがんを処置するためのポリヌクレオチドのToll様受容体9アゴニストの肺内投与 Active JP6792294B2 (ja)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US201562168449P 2015-05-29 2015-05-29
US201562168470P 2015-05-29 2015-05-29
US62/168,470 2015-05-29
US62/168,449 2015-05-29
US201562169321P 2015-06-01 2015-06-01
US201562169309P 2015-06-01 2015-06-01
US62/169,321 2015-06-01
US62/169,309 2015-06-01
US201662276767P 2016-01-08 2016-01-08
US62/276,767 2016-01-08
PCT/US2016/033817 WO2016196062A1 (en) 2015-05-29 2016-05-23 Intrapulmonary administration of polynucleotide toll-like receptor 9 agonists for treating cancer of the lung

Publications (3)

Publication Number Publication Date
JP2018521011A JP2018521011A (ja) 2018-08-02
JP2018521011A5 true JP2018521011A5 (cg-RX-API-DMAC7.html) 2019-06-20
JP6792294B2 JP6792294B2 (ja) 2020-11-25

Family

ID=56098419

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017561677A Active JP6792294B2 (ja) 2015-05-29 2016-05-23 肺のがんを処置するためのポリヌクレオチドのToll様受容体9アゴニストの肺内投与

Country Status (14)

Country Link
US (3) US9993495B2 (cg-RX-API-DMAC7.html)
EP (2) EP3302502B1 (cg-RX-API-DMAC7.html)
JP (1) JP6792294B2 (cg-RX-API-DMAC7.html)
KR (1) KR102779525B1 (cg-RX-API-DMAC7.html)
CN (1) CN107708706A (cg-RX-API-DMAC7.html)
AU (1) AU2016270782B2 (cg-RX-API-DMAC7.html)
CA (1) CA2987237A1 (cg-RX-API-DMAC7.html)
DK (1) DK3302502T3 (cg-RX-API-DMAC7.html)
ES (2) ES2752063T3 (cg-RX-API-DMAC7.html)
HK (1) HK1251471A1 (cg-RX-API-DMAC7.html)
IL (1) IL255903B (cg-RX-API-DMAC7.html)
MX (1) MX381587B (cg-RX-API-DMAC7.html)
RU (1) RU2017145940A (cg-RX-API-DMAC7.html)
WO (1) WO2016196062A1 (cg-RX-API-DMAC7.html)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8158768B2 (en) 2002-12-23 2012-04-17 Dynavax Technologies Corporation Immunostimulatory sequence oligonucleotides and methods of using the same
CA2964155A1 (en) * 2014-10-10 2016-04-14 Idera Pharmaceuticals, Inc. Treatment of cancer using tlr9 agonist with checkpoint inhibitors
WO2016081911A2 (en) 2014-11-21 2016-05-26 Northwestern University The sequence-specific cellular uptake of spherical nucleic acid nanoparticle conjugates
KR102779525B1 (ko) 2015-05-29 2025-03-12 다이나박스 테크놀로지 코퍼레이션 폐암을 치료하기 위한 폴리뉴클레오티드 Toll-유사 수용체 9 아고니스트의 폐내 투여
WO2018039629A2 (en) 2016-08-25 2018-03-01 Northwestern University Micellar spherical nucleic acids from thermoresponsive, traceless templates
US10463686B2 (en) 2016-09-15 2019-11-05 Idera Pharmaceuticals, Inc. Immune modulation with TLR9 agonists for cancer treatment
WO2018209270A1 (en) 2017-05-11 2018-11-15 Northwestern University Adoptive cell therapy using spherical nucleic acids (snas)
WO2020081398A1 (en) * 2018-10-14 2020-04-23 Dynavax Technologies Corporation Combination including a cpg-c type oligonucleotide and a pd-1 antagonist for treating breast cancer
JP2022505318A (ja) * 2018-10-18 2022-01-14 ドイチェス クレブスフォルシュンクスツェントルム 吸入用乾燥医薬組成物
CN111321159B (zh) * 2018-12-14 2023-12-12 中天(上海)生物科技有限公司 用于免疫调节的嵌合核酸分子及其应用
WO2020128893A1 (en) * 2018-12-21 2020-06-25 Pfizer Inc. Combination treatments of cancer comprising a tlr agonist
WO2021007160A1 (en) 2019-07-05 2021-01-14 Tambo, Inc. Trans-cyclooctene bioorthogonal agents and uses in cancer and immunotherapy
US11613755B2 (en) * 2019-12-31 2023-03-28 Industrial Technology Research Institute Nucleic acid-drug complex and use thereof
US12686870B2 (en) 2020-01-10 2026-07-21 Sbi Biotech Co., Ltd. TLR9 agonists
JP2023537066A (ja) 2020-08-07 2023-08-30 タンボ・インコーポレイテッド トランス-シクロオクテン生体直交型薬剤並びに癌及び免疫療法における使用
CN114099535B (zh) * 2020-12-10 2023-01-03 南京吉迈生物技术有限公司 Toll样受体9(TLR9)激动剂水凝胶免疫调节组合物
EP4267136A4 (en) * 2020-12-23 2025-02-05 Cascade Prodrug Inc. Combination therapy with a vinca alkaloid n-oxide and an immune checkpoint inhibitor
US20250009731A1 (en) 2021-11-08 2025-01-09 Nurix Therapeutics, Inc. Toll-like receptor therapy combinations with cbl-b inhibitor compounds
AU2023209887A1 (en) * 2022-01-21 2024-08-15 Trisalus Life Sciences, Inc. Methods of treating immune dysfunction in liver cancer with toll-like receptor agonists
WO2024186193A1 (ko) * 2023-03-08 2024-09-12 인제대학교 산학협력단 국소적 방사선 치료에서 전신성 항암 치료를 위한 조성물

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6218371B1 (en) * 1998-04-03 2001-04-17 University Of Iowa Research Foundation Methods and products for stimulating the immune system using immunotherapeutic oligonucleotides and cytokines
WO1999060166A1 (en) * 1998-05-21 1999-11-25 Isis Pharmaceuticals, Inc. Compositions and methods for the pulmonary delivery of nucleic acids
EP1364010B1 (en) 2000-12-27 2010-06-16 Dynavax Technologies Corporation Immunomodulatory polynucleotides and methods of using the same
TW200303759A (en) * 2001-11-27 2003-09-16 Schering Corp Methods for treating cancer
DE60334303D1 (de) * 2002-07-03 2010-11-04 Tasuku Honjo Immunpotenzierende zusammensetzungen
US8158768B2 (en) * 2002-12-23 2012-04-17 Dynavax Technologies Corporation Immunostimulatory sequence oligonucleotides and methods of using the same
DK1992635T3 (da) * 2002-12-23 2012-03-05 Dynavax Tech Corp Oligonukleotider med immunstimulatorisk sekvens og fremgangsmåder til anvendelse af disse
JP2007526253A (ja) * 2004-02-19 2007-09-13 コーリー ファーマシューティカル グループ,インコーポレイテッド 免疫刺激性ウイルスrnaオリゴヌクレオチド
CN101134046B (zh) * 2006-09-01 2011-10-05 中国医学科学院药物研究所 Tlr4和tlr9激动剂复方在抑制肿瘤转移中的应用
JP2012516352A (ja) * 2009-01-30 2012-07-19 イデラ ファーマシューティカルズ インコーポレイテッド Tlr9の合成アゴニスト
CA2836676A1 (en) * 2011-05-19 2012-11-22 Teva Pharmaceutical Industries Ltd. Method for treating non-small cell lung cancer
EA201690912A1 (ru) * 2013-11-05 2016-10-31 Когнейт Биосервисис, Инк. Комбинации ингибиторов контрольных точек и терапевтических средств для лечения рака
MX2017015311A (es) * 2015-05-29 2018-06-19 Merck Sharp & Dohme Combinacion de un anticuerpo anti-il-10 y un oligonucleotido tipo cpg-c para tratar cancer.
KR102779525B1 (ko) 2015-05-29 2025-03-12 다이나박스 테크놀로지 코퍼레이션 폐암을 치료하기 위한 폴리뉴클레오티드 Toll-유사 수용체 9 아고니스트의 폐내 투여
CA3020873A1 (en) * 2016-04-15 2017-10-19 Dynavax Technologies Corporation Intratumoral administration of particles containing a toll-like receptor 9 agonist and a tumor antigen for treating cancer

Similar Documents

Publication Publication Date Title
RU2017145940A (ru) Внутрилегочное введение полинуклеотидных агонистов толл-подобного рецептора 9 для лечения рака легких
Zhang et al. Chemotherapy reinforces anti-tumor immune response and enhances clinical efficacy of immune checkpoint inhibitors
Qiu et al. Clinical application of cytokines in cancer immunotherapy
Kirkwood Cancer immunotherapy: the interferon-α experience
Vacchelli et al. Trial Watch—Immunostimulation with cytokines in cancer therapy
Floros et al. Anticancer cytokines: biology and clinical effects of interferon-α2, interleukin (IL)-2, IL-15, IL-21, and IL-12
Kelly Immunotherapy for esophageal and gastric cancer
JP2023546009A5 (cg-RX-API-DMAC7.html)
JP2023546010A5 (cg-RX-API-DMAC7.html)
EP2782994B1 (en) Small molecule enhancer for dendritic cell cancer vaccines
Wang et al. Chimeric antigen receptor T cell therapy and other therapeutics for malignancies: Combination and opportunity
US10980859B2 (en) In vivo individualized systemic immunotherapeutic method and device
JP2025038139A (ja) 活性成分としてワクシニアウイルス及び顆粒球生成阻害剤を含む、がん治療用医薬組成物
US20100183542A1 (en) Synergism Between Activated Immune Cells and Conventional Cancer Therapies
IL288743B2 (en) Compositions and methods relating to erythrocytes with adhesive particles
Ficorella et al. Triplet chemotherapy in patients with metastatic colorectal cancer: toward the best way to safely administer a highly active regimen in clinical practice
US10335461B2 (en) Interferon therapy
JP2026028258A (ja) 併用処置
CN107299138B (zh) Cxcl4单抗治疗肿瘤及化疗后肿瘤加速再增殖基因筛选法
WO2024246868A1 (en) Methods of using alternating electric fields and checkpoint inhibitors
Salkeni et al. Resistance to immunotherapy: mechanisms and means for overcoming
TWI870704B (zh) 治療表達pd-l1之癌症的方法
Adachi et al. Tumoricidal effect of human macrophage-colony-stimulating factor against human-ovarian-carcinoma-bearing athymic mice and its therapeutic effect when combined with cisplatin
Van Besien et al. Phase II study of autologous transplantation with interleukin-2-incubated peripheral blood stem cells and posttransplantation interleukin-2 in relapsed or refractory non-Hodgkin lymphoma
Kiełbowski et al. Immunotherapeutics and other anticancer agents in the management of advanced gastric cancer